

26 June 2024

Ms Linda Lee  
Assistant Coroner for Warwickshire  
Warwick Justice Centre  
Newbold Terrace  
Royal Leamington Spa  
CV32 4EL

Sent via email: [REDACTED]

Our ref: EH-336418

Dear Ms Lee

I write in response to your regulation 28 report, regarding the very sad death of Mr David Riley. I would like to express my sincere condolences to Mr Riley's family.

We have reflected on the circumstances surrounding Mr Riley's death and the concerns raised in your report, in particular decisions regarding pausing of direct oral anticoagulants (DOACs).

Our guideline on [venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism](#) [NG89] covers VTE risk assessment but does not specifically cover pausing of DOACs such as apixaban. It is not possible to cover all clinical circumstances in our guidelines. Nevertheless, NICE will further consider the issues raised through our guideline surveillance process to see if an update to the guideline is required.

The [Clinical Knowledge Summary \(CKS\) on anticoagulation – oral](#) may also be relevant to this case. The CKS gives prescribing and management information for adults receiving apixaban, dabigatran, edoxaban, and rivaroxaban and covers whether [apixaban](#) should be stopped if surgery or dental treatment is required. We commission an external company, Agilio Software, to develop the CKS which are designed to summarise the evidence on the treatment of specific health conditions that present in primary care. They use a variety of sources and may include NICE guidance, if there is any that is relevant, but they use many other sources too. We publish them on our website as a source of advice and information for health professionals working in primary care, but they do not constitute NICE guidance.

We will share your report with Agilio Software for their awareness.

Please do let me know if you require any further information and again, I offer my sincerest condolences to Mr Riley's family.

Yours sincerely,

[Redacted Signature]

[Redacted Name]  
**Chief Executive**